Condition
Enlarged Prostate (BPH)
Total Trials
5
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
5Total
Not Applicable (5)
Trial Status
Recruiting2
Active Not Recruiting1
Not Yet Recruiting1
Terminated1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07631286Not ApplicableRecruitingPrimary
Ejaculatory-Sparing HoLEP vs Standard HoLEP
NCT07632742Not ApplicableRecruitingPrimary
Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial
NCT05330520Not ApplicableActive Not Recruiting
Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients Who Completed 12 Months of Follow-Up Post Implantation (Continuation Study for Study BM-011-IL)
NCT07580404Not ApplicableNot Yet Recruiting
Emsella for Reducing tSUI After HOLEP
NCT04398966Not ApplicableTerminated
Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia
Showing all 5 trials